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peared to have lymph node involvement at pathologic stag-
ing.25,26 It may well be that patients with extracapsular
lymph node involvement will be a subset of patients bene-
fiting from such adjuvant regimen.
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Discussion
Dr Mark Krasna (Baltimore, Md). I congratulate Dr Lerut and
his colleagues for an excellent presentation and thank them for
forwarding their manuscript to me. This study retrospectively
reviewed 195 patients with T3 esophageal cancer undergoing R0
resection over a 10-year period. Sixty-eight of these also under-
went neck dissection as part of a radical 3-field esophagectomy;
83% of these patients had positive lymph nodes. In fact, 1 of the
pathologists on this study reviewed approximately 6000 lymph
node specimens to determine evidence of extracapsular versus
intracapsular lymph node invasion in these lymph nodes. Your
group has shown a remarkable 5- and 9-year survival of 57% and
38% for N0 patients and 26% and 18% for N1 patients. These
results are truly admirable. Your group has consistently shown that
esophagectomy can be done with low mortality and excellent
5-year survival. More importantly, you have shown the signifi-
cance of lymph node involvement as an independent prognostica-
tor in patients with esophageal cancer.
Dr F. Henry Ellis and I, in a review of over 450 patients at the
Lahey Clinic, found that lymph nodes were the single most im-
portant prognostic indicator in patients with esophageal cancer.1
Moreover, we, too, found that the number of involved nodes was
important. Dr Tom Rice has also shown the paramount importance
of lymph node spread in esophageal cancer. He has demonstrated
as well the very important relationships between the T and N
classifications. Finally, Dr Skinner and later DeMeester have dem-
onstrated the significance of lymph node positivity and the impor-
tance of the numbers of lymph nodes involved and proposed a new
so-called “WNM classification” that included an N1 and N2 clas-
sification.
It seems therefore that we have 2 challenges regarding staging
of esophageal cancer: first, to modify the existing lymph node N
stage to better reflect the significance of multiple lymph node
involvement and consider celiac and cervical lymph nodes, which
are being resected together with other lymph node stations; second,
to optimize the methods of staging lymph nodes in esophageal
cancer patients’ pretreatment.
I have 3 questions for you, Dr Lerut: (1) Do you have data on
lymph node involvement, meaning intracapsular versus extracap-
sular, by the lymph node level according to the lymph node map,
or at least can you define them by chest involvement, neck in-
volvement, and abdomen involvement? (2) This was a highly
selected group of 195/429 patients with adenocarcinoma undergo-
ing R0 resections at your institution. How did the other 236
patients fare? (3) Finally, and practically, how should we use the
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information presented? If EUS–fine-needle aspiration is negative,
should we proceed with a thoracoscopic and laparoscopic lymph
node staging as is done at University of Maryland on protocol?
This would seem the only way to allocate neoadjuvant therapy;
otherwise we are left only with the choice of doing adjuvant
therapy, as you mentioned.
I enjoyed the presentation. Your group has set an attainable
gold standard for lymph node dissection and survival in esopha-
geal cancer.
Dr Lerut. Thank you very much, Dr Krasna, for your nice
words and comments. I think we at least have in common that we
both are quite frustrated with the actual staging system. As to your
first question on the data of intracapsular and extracapsular lymph
node involvement by each lymph node station, we did not do that
study, because, first of all, it is a very tedious study, and, second,
we felt that that would fragment the patient material too much,
which probably would result in inadequacy in the interpretation of
the results. But I roughly can say that for the lymph node involve-
ment in the neck, we had about 15% positive lymph nodes in the
neck, about 30% positive lymph nodes in the chest, and over 50%
positive lymph nodes in the abdomen, which I think is the common
repartition, except for, of course, the third field, which is some-
thing that few centers are doing, but those 15% were clearly
unexpected or unforeseen lymph nodes that were involved. As to
your second question on how the other patients fared, the overall
survival for the whole group was 39% at 5 years. We had an 83%
R0 resection rate. There is a distinction between the Barrett’s and
the non-Barrett’s, the Barrett’s being mainly the distal esophagus,
with roughly about 50% 5-year survival; for the GEJ the 5-year
survival was at 35%. Overall, the lymph node negatives for the 2
groups together, Barrett’s and non-Barrett’s, were about 70%
5-year survival, and for the GEJ there was 100% at stage I, and I
think there was something like 75% at stage II and about 30% at
stage III, 5-year survival. The third question, of course, is an open
question, how should we use these results that have been shown.
Honestly, I do not have the answer myself. It is a very troublesome
finding in terms of using it for our indications for commencing
induction therapy, because I have the feeling that with 1 to 6
positive lymph nodes with intracapsular lymph node involvement,
there is probably no need for induction therapy, as they fare as well
as you can get with induction therapy. The problem now is how do
we access intracapsular or extracapsular involvement during clin-
ical staging, because fine-needle aspiration can only say yes or no
involvement. The answer may be in the preoperative staging with
thoracoscopy and laparoscopy, but then you need to do it thor-
oughly, and you showed in your multicenter study that this is
difficult. As I recall, it was possible to sample subcarinal and left
gastric, which are easier to access, in about 70% of all the groups.
So I think that will be a difficult job to do, and perhaps you are the
only one in the world who can do it properly. So I think our first
concern should be to validate these results by other centers. I think
that is what we need to do. And then I think we have to perhaps
make recommendations of changing the TNM staging system.
Dr Alan G. Casson (Halifax, Nova Scotia, Canada). Dr Lerut,
I also enjoyed your presentation. This series includes adenocarci-
nomas of the esophagus, type I, and also the esophagogastric
junction, type II. Could you tell us exactly how many were in each
group? Second, did you look at patterns of metastasis between
each group? Did you observe any extracapsular metastasis mac-
roscopically at surgery or was this purely a histologic study?
Dr Lerut. Thank you, Dr Casson. The repartition of how many,
I think, if I recall well, it was roughly a 50/50 representation, but
I am not so sure about the exact numbers. As to the pattern of
lymph node metastasis, obviously there is a higher incidence of
abdominal positive lymph nodes the more you go downward with
the location of the primary tumor, and there was, of course, the
surprising finding of having the positive lymph nodes in the neck
with the patients with distal esophageal adenocarcinoma, although
we also had in the T3 setting some patients with GEJ tumors who
had positive lymph nodes in the neck. The study was in fact a
histological study, it was not a macroscopic study, although it is
obvious that some of those lymph nodes can be seen with the
naked eye. In relation to the last question of Dr Krasna, the
introduction of PET scan of course may reveal some of those
bigger lymph nodes that obviously have extracapsular lymph node
involvement. We did a small study, which is not ready yet, trying
to find out whether PET is indeed helping us discriminate between
extracapsular and intracapsular, but unfortunately the preliminary
results are showing that this is not the case.
Dr James D. Luketich (Pittsburgh, Pa). I really enjoyed your
talk, Dr Lerut, and I admire your ability to get your pathologists to
work on retrospective specimens to that degree. We have a hard
time doing it prospectively.
My question is, the intracapsular versus extracapsular, did you
note any difference in size, in millimeters of the lymph nodes? And
by EUS, with your newer US technologies, are you seeing the
ability to begin to define this preoperatively by endoscopic ultra-
sound?
Also, along those same lines of preoperative staging, there have
been 1 or 2 very provocative papers on C11 choline as being much
more sensitive and specific for predicting lymph node involvement
by PET scanning with this new tracer. Do you have any experience
with that?
I would also like to make a comment. We just published a paper
in Clinical Cancer Research on our node-negative patients, and by
reverse transcriptase-polymerase chain reaction positivity alone,
we were able to predict recurrence in a very high proportion, and
I wonder what molecular studies you are doing on your node-
negative patients.
Dr Lerut. Thank you, Dr Luketich. As to the first question,
that’s a tough question. First of all, let me pay my tribute to my
pathologist, who really is a highly motivated individual who wants
to do all this work, but I couldn’t ask her to measure the size as
well, because she had to go through something like, as you said,
6000 or more lymph nodes.
As to the potential of EUS to discriminate, I think this is new
information and we have been discussing it with our people who
are doing the echoendoscopy. I think we have to learn whether it
is possible indeed to make this discrimination.
What you said about the PET scan, C11 choline, we have used
that in our center, but that did not show any significant information
as far as I can recall. I have no data on immunostaining or other
molecular biology techniques for the lymph node negatives at this
moment. This is a project that is on the way, but I have no data on
that.
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